Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 27, 2011

Novartis submits NVA237 for Japanese approval

Novartis has submitted NVA237, the company's new treatment for chronic obstructive pulmonary disease, for approval in Japan.

By Liam Stoker

Novartis has submitted NVA237, the company’s new treatment for chronic obstructive pulmonary disease, for approval in Japan.

The drug, which was submitted for European approval in September 2011 under the brand name Seebri Breezhaler, is a long-acting muscarinic antagonist designed to be taken once-daily.

Novartis originally licensed the drug from Japanese pharmaceutical company Sosei and UK-based Vectura in April 2005.

Novartis last week signed Eisai as a co-promoter of the drug should it receive Japanese approval.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU